Dr. John I. Bell, MD, is a Chairman-Partnership Board at Oxford Centre for Diabetes Endocrinology & Metabolism, an Advisor at Biospring Management Partners LP, a Chairman at GMEC Management Co. Ltd., a Chairman at Office for Strategic Co-ordination of Health Research, a Chairman at The Oxford Health Alliance and a Non-Executive Director at The Jenner Institute Laboratories.
He is on the Board of Directors at Immunocore Holdings Plc, Genentech, Inc., Genomics England Ltd., Oxford Science Enterprises PLC, Oxford University Hospitals NHS Trust, The Gray Laboratory Cancer Research Trust, Rhodes Trust and The Ewelme Almshouse Charity.
Dr. Bell was previously employed as a President by Academy of Medical Sciences, a Non-Executive Director by Roche Holding AG, a Non-Executive Director by Oxagen Ltd., a Founder by The Wellcome Trust Centre for Human Genetics, a Chairman-Medicine Department & Professor by University of Oxford, an Independent Non-Executive Director by Avidex Ltd., a Non-Executive Director by F. Hoffmann-La Roche Ltd., and a Chairman by Sensyne Health Plc.
He also served on the board at Atopix Therapeutics Ltd. and Powderject Pharmaceuticals Plc.
He received his undergraduate degree from Magdalen College School Oxford Ltd, an undergraduate degree from the University of Alberta and a doctorate degree from Magdalen College School Oxford Ltd.